Valuation: Sangamo Therapeutics, Inc.

Market Cap 45.57M 41.56M 38.43M 34.68M 65.31M 4.26B 67.89M 464M 183M 2.3B 171M 167M 7.26B P/E 2024
-2.1x
P/E 2025 -0.96x
Enterprise Value 51.42M 46.89M 43.36M 39.13M 73.69M 4.8B 76.6M 524M 207M 2.59B 193M 189M 8.19B EV / Sales 2024
3.49x
EV / Sales 2025 3.72x
Free-Float
99.07%
Yield 2024 *
-
Yield 2025 -
1 week+3.77%
Current month-5.17%
1 month-0.18%
3 months-31.03%
6 months-13.79%
Current year-73.81%
1 week 0.1
Extreme 0.103
0.12
1 month 0.07
Extreme 0.07
0.13
Current year 0.01
Extreme 0.01
0.6
1 year 0.01
Extreme 0.01
0.6
3 years 0.01
Extreme 0.01
3.18
5 years 0.01
Extreme 0.01
9.3
10 years 0.01
Extreme 0.01
27.5
Manager TitleAgeSince
Chief Executive Officer 63 01/06/2016
Director of Finance/CFO 47 03/02/2026
Chief Tech/Sci/R&D Officer - 29/05/2023
Director TitleAgeSince
Chairman 70 01/06/2017
Director/Board Member 63 01/06/2016
Director/Board Member 68 01/06/2016
Date Insider Type Main position Quantity % Market Cap. Importance
5/25/26 A Tax

General Counsel

-4,036 0.0010%
5/25/26 A Tax

Executive/Senior Manager

-4,036 0.0010%
5/25/26 A Tax

Chief Executive Officer

-12,613 0.0030%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+3.77%-73.89%-71.41% 45.57M
-1.34%-3.09%+56.10%+68.83% 65.45B
-0.40%-3.45%+7.35%+89.93% 58.93B
+0.60%+0.75%+26.70%+87.85% 55.21B
-2.34%-3.90%+10.90%+115.97% 46.1B
+0.09%-6.08%+18.67%+25.90% 42.49B
-2.58%+0.24%+18.54%+41.28% 35.56B
-1.76%-11.56%+126.44%+649.27% 34.57B
+0.54%0.00%+78.37%+59.01% 32.46B
-1.69%-0.79%-40.58%+382.68% 26.28B
Average -0.88%-2.69%+22.86%+144.93% 40B
Weighted average by Cap. -0.90%-3.29%+33.69%+143.50%

Financials

2024 2025
Net sales 57.8M 52.71M 48.74M 43.98M 82.84M 5.4B 86.1M 589M 233M 2.92B 217M 212M 9.21B 39.55M 36.07M 33.35M 30.1M 56.69M 3.7B 58.92M 403M 159M 1.99B 148M 145M 6.3B
Net income -97.94M -89.32M -82.59M -74.53M -140M -9.15B -146M -997M -394M -4.94B -367M -360M -15.6B -123M -112M -104M -93.55M -176M -11.49B -183M -1.25B -495M -6.2B -461M -452M -19.58B
Net Debt -11.35M -10.35M -9.57M -8.64M -16.27M -1.06B -16.91M -116M -45.7M -573M -42.59M -41.7M -1.81B 5.85M 5.33M 4.93M 4.45M 8.38M 546M 8.71M 59.55M 23.54M 295M 21.94M 21.48M 931M
Projected Income Statement - Annual - Sangamo Therapeutics, Inc.
Logo Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. is a genomic medicine company that pioneered the development of zinc finger and capsid delivery technologies to address serious neurological and rare diseases. The Company's assets include clinical-stage programs ST-503 for chronic neuropathic pain and giroctocogene fitelparvovec for hemophilia A, as well as its cell therapy and regulatory T cell (T-Reg) assets. The Company is developing ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. ST-503 uses an AAV vector carrying an engineered zinc finger repressor (ZFR) to specifically target the human gene, SCN9A, that encodes the Nav1.7 sodium channel and is critical for pain signaling. Giroctocogene fitelparvovec is a liver-tropic rAAV6 vector carrying a B-domain deleted F8 gene that is delivered through a single IV infusion. The Company is operating under court supervision in Chapter 11.
Employees
142
Date Price Change Volume
18/11/26 $0.1100 0.00% 211,891
17/11/26 $0.1100 +1.01% 333,804
16/11/26 $0.1089 -6.92% 871,736
13/11/26 $0.1170 +6.36% 219,301
12/11/26 $0.1100 +3.77% 731,530
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Sangamo Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SGMOQ Stock